A defining characteristic of the solid TME is profound hypoxia—an oxygen-deprived milieu that has been implicated in metabolic dysfunction and immune exhaustion of T cells. Experimental findings illustrate that under hypoxic conditions, CAR T cells rapidly diminish their effector capabilities while upregulating inhibitory receptors such as PD-1 and TIM-3, hallmarks of T cell exhaustion. This metabolic constraint coupled with intense immunosuppressive signaling compounds the difficulty of achieving durable tumor control.

Beyond hypoxia, the immune landscape of solid tumors is dominated by suppressive myeloid populations, including myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs). These cell types secrete inhibitory cytokines such as TGF-β and IL-10, which blunt cytotoxic T cell function. Furthermore, they manipulate the metabolic competition within the tumor niche by depleting essential nutrients like arginine and glucose, effectively starving T cells of critical resources necessary for their proliferation and persistence. This metabolic tug-of-war epitomizes the sophisticated tumor strategies to evade immunologic eradication.

Physical barriers imposed by the dense extracellular matrix and chaotic vasculature further restrict immune effector trafficking into the tumor core. Preclinical orthotopic models, notably in pancreatic and gastric cancers, demonstrate that CAR T cells preferentially accumulate at the tumor periphery, rarely infiltrating the densely packed core regions where malignant cells reside. This uneven distribution results in incomplete and heterogeneous tumor killing, thereby undermining the overall efficacy of the treatment. Coupled with this is the challenge of limited CAR T cell persistence in vivo: rapid expansion is often followed by contraction and eventual disappearance from circulation, paralleling tumor relapse and disease progression.

Another persistent challenge is antigen heterogeneity and specificity within solid tumors. Tumor-associated antigens like Claudin-18.2 and mesothelin, while promising targets, exhibit heterogeneous expression across cancer cell populations. This leads to selective pressure favoring antigen-negative clones, which expand and contribute to tumor escape. Moreover, many of these antigens are expressed at low levels in normal tissues, risking off-tumor, on-target toxicity. Clinical data from phase II trials targeting Claudin-18.2 vividly highlight this risk, showing significant gastric mucosal damage in a notable fraction of patients, underscoring the difficulty in identifying truly tumor-exclusive targets.

Adaptive immune resistance further complicates treatment outcomes. Tumors frequently evolve under immune pressure by altering antigen presentation pathways, enabling them to evade recognition and destruction by therapeutic T cells. The role of endogenous T cells in preventing antigen-loss mediated escape is increasingly clear, suggesting that single-antigen targeted therapies may be insufficient in isolation. Cytokine responses in the TME, particularly involving interferon-gamma (IFN-γ), embody a paradoxical role: while IFN-γ can enhance immune activation, it also induces immunosuppressive PD-L1 expression within the tumor, fostering a feedback loop of adaptive inhibition. This biological insight paves the way for rational combination therapies integrating immune checkpoint blockade with adoptive cell therapies.

Safety concerns remain a critical barrier to the broader application of ACT and ICEs in solid tumors. Cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS) are predominant adverse events arising from these therapies. These syndromes represent hyperinflammatory states driven by exuberant activation of immune effectors post-infusion, rather than mere dose-dependent toxicities. Their incidence correlates with tumor burden and baseline patient inflammatory milieu. Recent clinical trials of Claudin-18.2 CAR T cells report very high rates of CRS—exceeding 95%—although mostly mild-to-moderate in severity. BiTEs such as tarlatamab also induce substantial CRS rates, necessitating cautious dose escalation and inpatient monitoring protocols.

ICANS, while less frequent than CRS, poses significant clinical challenges due to its unpredictable neurological manifestations, including encephalopathy and seizures. Management often requires high-dose corticosteroids and temporarily halting therapy, complicating trial design and clinical management. Additionally, high-dose interleukin-2 (IL-2) administration following tumor-infiltrating lymphocytes (TIL) infusion triggers capillary leak syndrome (CLS), characterized by vascular permeability and hypotension, underscoring the delicate balance between therapeutic intensity and tolerability in ACT trials.

Compounding these acute toxicities is the emerging recognition of immune effector cell–associated hemophagocytic lymphohistiocytosis–like syndrome (IEC-HS), a severe hyperinflammatory condition marked by cytopenias, coagulopathy, and multiorgan dysfunction, often manifesting during the resolution phase of CRS. Its management frequently necessitates intensified immunosuppressive strategies, including high-dose steroids alongside agents such as anakinra and ruxolitinib. The acknowledgment of IEC-HS as a discrete clinical entity has informed evolving toxicity mitigation frameworks, aiming to maximize therapeutic benefit while minimizing life-threatening adverse events.

The innovation in immunotherapy has been paralleled by the development of strategies to mitigate these toxicities. Step-up dosing regimens for T cell engagers and selective corticosteroid prophylaxis in high-risk cohorts are becoming integral components of clinical protocols, striving to strike a balance between efficacy and safety. These approaches reflect an increasingly nuanced understanding of the inflammatory cascades unleashed by immune therapies and a commitment to enhancing patient outcomes.

Manufacturing complexities add another dimension to the challenges faced in solid tumor immunotherapy. Adoptive cell therapy often involves labor-intensive, patient-specific processes of T cell isolation, genetic modification, expansion, and quality control. Variability in expansion potential attributable to individual donor variability and T cell fitness foreshadows significant scalability and cost hurdles. Clinical translation will necessitate innovations in manufacturing to enable broad accessibility and economic viability.

As research advances, it becomes clear that overcoming the solid tumor microenvironment’s multifactorial resistance mechanisms demands multidimensional approaches. Incorporating metabolic reprogramming, improving trafficking, selecting optimal antigen targets, and developing robust combinatorial regimens including checkpoint inhibitors are essential. Equally important is refining dosing paradigms and supportive care to mitigate toxicities without blunting therapeutic efficacy.

In summary, while adoptive cell therapies and immune cell engagers have revolutionized hematologic cancer treatment, their application in solid tumors remains beset by formidable biological barriers and safety concerns. Progress hinges on a deep mechanistic understanding of the tumor microenvironment and immune dynamics, alongside innovative clinical strategies to enhance trafficking, persistence, and antigen specificity. Coupled with careful toxicity management and manufacturing advancements, these efforts are poised to unlock the full potential of immunotherapy for patients battling solid malignancies.

The emerging paradigm underscores the essential interplay between tumor biology, immune evasion, and therapeutic design. By unraveling these complex interactions and tailoring interventions accordingly, the field stands on the threshold of transforming the landscape of solid tumor cancer therapy, offering renewed hope for durable remission and improved survival outcomes.

Subject of Research: Advances in cancer immunotherapy focusing on adoptive cell therapy and immune cell engagers for solid tumors.

Article Title: Advances in cancer immunotherapy: adoptive cell therapy and immune cell engagers in solid tumours.

Article References:
Panasci, J., Park, C.L., Tran, B. et al. Advances in cancer immunotherapy: adoptive cell therapy and immune cell engagers in solid tumours. Br J Cancer (2026). https://doi.org/10.1038/s41416-026-03450-w

Image Credits: AI Generated

DOI: 27 April 2026

Bowel cancer poses a significant clinical challenge due to its heterogeneous growth rates. Traditional chemotherapeutic regimens primarily assault rapidly dividing cancer cells, leaving behind quiescent or slow-cycling populations that evade destruction and later give rise to relapse. These residual cells are often more aggressive and less responsive to subsequent treatments, underscoring an urgent need for therapies capable of overcoming this resilience.

Leveraging the advancements made in adoptive cell therapy, which has revolutionized treatment for hematological malignancies such as leukemia, the UCL researchers turned their attention to a far less abundant, yet intriguing, population of immune cells termed γδT cells. Unlike their more common αβT cell counterparts that identify threats through antigen presentation via MHC molecules, γδT cells possess innate-like abilities to detect cellular stress markers without reliance on classical antigen presentation, enabling a rapid and versatile immune response.

Previous UCL investigations demonstrated the feasibility of engineering γδT cells to target osteosarcoma cells effectively. However, extending this success beyond the bone microenvironment and into the complex milieu of solid tumors remained uncharted territory. To explore this, scientists isolated γδT cells from healthy donors and employed lentiviral vectors to transduce these cells with a gene encoding a stabilized interleukin-15 (stIL-15). This cytokine variant is known to enhance T cell survival and proliferation, thereby equipping the γδT cells with prolonged viability and sustained cytotoxic potential.

To amplify their anti-tumor efficacy, a subset of these engineered γδT cells was further modified to express an antibody against B7-H3, an immune checkpoint protein commonly overexpressed on bowel cancer cells. This modification not only facilitated targeted recognition but also activated dual cytolytic mechanisms: Antibody-Independent Cytotoxicity (AIC), the intrinsic killing pathway of γδT cells, and Antibody-Dependent Cellular Cytotoxicity (ADCC), a potent immune-mediated attack triggered through the antibody engagement.

The functional capacity of these modified immune cells was rigorously evaluated using patient-derived tumor organoids—three-dimensional cellular culture systems that authentically replicate the tumor microenvironment’s complexity and heterogeneity. Across over 1,000 experimental conditions encompassing organoids from ten bowel cancer patients, the supercharged γδT cells exhibited remarkable persistence and potency. Unlike unmodified γδT cells, which succumbed to tumor-mediated immunosuppression and cellular exhaustion, engineered cells maintained robust viability and cytotoxic function over extended periods.

Intriguingly, when the γδT cells relied solely on their native antibody-independent killing, tumor cells orchestrated adaptive resistance by altering immune signaling pathways—effectively “rewiring” the γδT cells into a diminished state. This discovery highlights the adaptive plasticity of tumors and their capacity to undermine monotherapeutic immune attacks. Conversely, multi-modal attack strategies, empowered by the B7-H3 antibody’s facilitation of both AIC and ADCC, restored the functional wiring of γδT cells. This dual-pronged assault decisively eliminated cancer cells, including slow-dividing subsets impervious to chemotherapy.

These findings were contextualized by the co-corresponding authors, Professor Chris Tape and Dr. Jonathan Fisher, who emphasized the translational implications. Professor Tape articulated, “By providing γδT cells with multiple avenues to attack, we can circumvent the tumor’s defensive mechanisms and sustain an effective anti-cancer response. This advancement propels us closer to novel immunotherapies for refractory bowel cancer.” Dr. Fisher, the architect of the engineered γδT cell platform, highlighted the broader potential to extend these therapies across other solid tumors, a notoriously difficult arena for immunotherapies due to complex tumor-immune interactions.

A pivotal component of the research was deploying UCL’s ‘phenoscaping’ technology, a sophisticated single-cell analytical framework that offers unprecedented resolution in mapping cellular phenotypes and dynamic interactions within tumor-immune ecosystems. This tool elucidated the cellular trajectories and molecular adaptations driving the differential outcomes between engineered and unmodified γδT cell populations, informing rational design enhancements for future therapeutic iterations.

Central to the promise of γδT cell-based immunotherapy is their unique biological distinction from αβT cells, which dominate current T cell therapies but require autologous sourcing to minimize graft-versus-host disease and maximize efficacy. γδT cells possess the intrinsic capacity for allogeneic transfer, meaning therapeutically potent cells could be derived from healthy donors, thereby surmounting logistical and manufacturing obstacles that hamper widespread accessibility of personalized T cell therapies.

Collectively, the research underscores a critical paradigm shift: engineering immune cells not merely for specificity but for resilience and multi-modal functionality can empower sustained tumor eradication even in the face of dynamic tumor resistance mechanisms. As these promising preclinical outcomes pave the way for clinical translation, they ignite hope for more durable, effective, and universally accessible immunotherapies against bowel cancer and potentially other recalcitrant solid malignancies. The study was generously supported by renowned organizations including Cancer Research UK, the Medical Research Council, and the Wellcome Trust, underscoring the global commitment to advancing cancer treatment frontiers.

Subject of Research: Cells
Article Title: 10.1158/0008-5472.CAN-25-1890
News Publication Date: 14-Oct-2025
Web References: 10.1158/0008-5472.CAN-25-1890
References: Cancer Research (Journal)
Keywords: Cancer cells